IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025
IGC Pharma (NYSE American:IGC) has scheduled a conference call and webcast for Monday, June 30, 2025, at 11:00 a.m. ET to discuss their fiscal year 2025 operational progress and financial results for the period ended March 31, 2025. The financial results will be released before market opening on the same day.
Shareholders and investors can participate via phone by dialing (888) 506 0062 (US) or (973) 528 0011 (International) using access code 370284. A webcast will be available, and a replay can be accessed until July 31, 2025.
IGC Pharma (NYSE American:IGC) ha programmato una conference call e una webcast per lunedì 30 giugno 2025 alle 11:00 ET per discutere i progressi operativi e i risultati finanziari dell'anno fiscale 2025, relativi al periodo terminato il 31 marzo 2025. I risultati finanziari saranno pubblicati prima dell'apertura del mercato nello stesso giorno.
Azionisti e investitori possono partecipare telefonicamente chiamando il numero (888) 506 0062 (USA) o (973) 528 0011 (Internazionale) utilizzando il codice di accesso 370284. Sarà disponibile una webcast e la registrazione potrà essere rivista fino al 31 luglio 2025.
IGC Pharma (NYSE American:IGC) ha programado una llamada de conferencia y una transmisión en vivo para el lunes 30 de junio de 2025 a las 11:00 a.m. ET para discutir el progreso operativo y los resultados financieros del año fiscal 2025, correspondiente al período finalizado el 31 de marzo de 2025. Los resultados financieros se publicarán antes de la apertura del mercado ese mismo día.
Los accionistas e inversores pueden participar por teléfono llamando al (888) 506 0062 (EE.UU.) o al (973) 528 0011 (Internacional) usando el código de acceso 370284. Habrá una transmisión en vivo disponible y la repetición podrá ser vista hasta el 31 de julio de 2025.
IGC Pharma (NYSE American:IGC)는 2025년 6월 30일 월요일 오전 11시 ET에 2025 회계연도 운영 진행 상황 및 2025년 3월 31일 종료 기간의 재무 결과를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 예정했습니다. 재무 결과는 같은 날 시장 개장 전에 공개됩니다.
주주 및 투자자는 (888) 506 0062 (미국) 또는 (973) 528 0011 (국제)로 전화하여 액세스 코드 370284를 사용해 참여할 수 있습니다. 웹캐스트가 제공되며 2025년 7월 31일까지 재방송을 시청할 수 있습니다.
IGC Pharma (NYSE American:IGC) a programmé une conférence téléphonique et un webinaire pour le lundi 30 juin 2025 à 11h00 ET afin de discuter des progrès opérationnels et des résultats financiers de l'exercice 2025 pour la période close au 31 mars 2025. Les résultats financiers seront publiés avant l'ouverture des marchés le même jour.
Les actionnaires et investisseurs peuvent participer par téléphone en composant le (888) 506 0062 (États-Unis) ou le (973) 528 0011 (International) en utilisant le code d'accès 370284. Un webinaire sera disponible, et un replay pourra être consulté jusqu'au 31 juillet 2025.
IGC Pharma (NYSE American:IGC) hat eine Telefonkonferenz und einen Webcast für Montag, den 30. Juni 2025, um 11:00 Uhr ET angesetzt, um den operativen Fortschritt und die Finanzergebnisse für das Geschäftsjahr 2025, das am 31. März 2025 endete, zu besprechen. Die Finanzergebnisse werden am selben Tag vor Börsenöffnung veröffentlicht.
Aktionäre und Investoren können telefonisch teilnehmen, indem sie (888) 506 0062 (USA) oder (973) 528 0011 (international) wählen und den Zugangscode 370284 verwenden. Ein Webcast wird verfügbar sein, und eine Wiedergabe kann bis zum 31. Juli 2025 abgerufen werden.
- None.
- None.
POTOMAC, MARYLAND / ACCESS Newswire / June 27, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company will host a conference call and webcast on Monday, June 30, 2025, at 11:00 a.m. Eastern Time to review the Company's operational progress for the fiscal year ended March 31, 2025. The Company will release its fiscal year 2025 financial results that day before the market opens.
To participate in the call by phone, dial (888) 506 0062 approximately five minutes prior to the scheduled start time. International callers please dial (973) 528 0011. Callers should use access code: 370284.
Investors may access the live webcast via the following link:https://www.webcaster4.com/Webcast/Page/2938/52547
A replay of the teleconference will be available at the above link until July 31, 2025.
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Qs filed with the SEC on August 7, 2024, November 12, 2024, and February 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian/Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
When is IGC Pharma's fiscal year 2025 earnings call?
How can I access IGC Pharma's fiscal year 2025 earnings call?
When will IGC Pharma release its fiscal year 2025 financial results?
How long will the replay of IGC Pharma's earnings call be available?
